Tuesday, June 30, 2026

𝐔𝐛𝐞𝐫, 𝐒𝐨𝐜𝐢𝐚𝐥 𝐌𝐞𝐝𝐢𝐚 & 𝐃𝐞𝐩𝐨-𝐏𝐫𝐨𝐯𝐞𝐫𝐚 𝐋𝐞𝐚𝐝 𝐚 𝐂𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐞𝐝 𝐌𝐨𝐧𝐝𝐚𝐲

We tracked 126 new MDL filings Monday, with intake concentrated in a handful of firms rather than spread across the bar. The 𝐔𝐛𝐞𝐫 𝐏𝐚𝐬𝐬𝐞𝐧𝐠𝐞𝐫 𝐒𝐞𝐱𝐮𝐚𝐥 𝐀𝐬𝐬𝐚𝐮𝐥𝐭 𝐋𝐢𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧 (𝐌𝐃𝐋 𝟑𝟎𝟖𝟒) led with 22 new complaints — 𝐂𝐮𝐭𝐭𝐞𝐫 𝐋𝐚𝐰 𝐏𝐂 filed 21 of them, a near-total single-firm push that reads as coordinated inventory deployment, with 𝐍𝐚𝐜𝐡𝐚𝐰𝐚𝐭𝐢 𝐋𝐚𝐰 𝐆𝐫𝐨𝐮𝐩 adding the lone remainder. The 𝐒𝐨𝐜𝐢𝐚𝐥 𝐌𝐞𝐝𝐢𝐚 𝐀𝐝𝐨𝐥𝐞𝐬𝐜𝐞𝐧𝐭 𝐀𝐝𝐝𝐢𝐜𝐭𝐢𝐨𝐧 𝐋𝐢𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧 (𝐌𝐃𝐋 𝟑𝟎𝟒𝟕) followed with 19, led by 𝐊𝐞𝐥𝐥𝐞𝐫 𝐏𝐨𝐬𝐭𝐦𝐚𝐧 𝐋𝐋𝐂 (12) and 𝐋𝐢𝐞𝐟𝐟 𝐂𝐚𝐛𝐫𝐚𝐬𝐞𝐫 (2). The 𝐃𝐞𝐩𝐨-𝐏𝐫𝐨𝐯𝐞𝐫𝐚 𝐋𝐢𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧 (𝐌𝐃𝐋 𝟑𝟏𝟒𝟎) drew 15 meningioma suits — 𝐌𝐮𝐫𝐩𝐡𝐲 𝐋𝐚𝐰 𝐅𝐢𝐫𝐦 (5) and 𝐒𝐜𝐡𝐥𝐢𝐜𝐡𝐭𝐞𝐫 𝐁𝐨𝐠𝐚𝐫𝐝 𝐋𝐋𝐏 (3) — even as that docket operates under a tentative settlement in principle, a sign firms are still positioning claims ahead of any eligibility cutoff.

See the full filing feed and firm-level breakdowns here.

FDA Connects Infant Formula Recalls to Common Supplier in SDNY Litigation

On June 27, 2026, the Food and Drug Administration disclosed that a multistate outbreak of infant botulism linked to a voluntary recall of Nara Organics infant formula shares a common supply chain with the contaminated products at the center of In re: ByHeart, Inc., Infant Formula Marketing, Sales Practices, and Products Liability Litigation (MDL 3178). Investigators traced the organic whole milk powder used by both brands to supplier Organic West Milk and a Dairy Farmers of America drying facility, exposing a critical gap in early traceforward efforts due to incomplete customer records. The discovery of this shared supplier adds significant momentum to the federal litigation in the Southern District of New York, where families allege severe neurological injuries from the toxin. While the regulator noted that sample testing is ongoing and has not yet yielded a positive contamination result for Nara Organics, the revelation of a unified supply-chain vector is expected to streamline discovery and expand the scope of liability in the consolidated proceeding.

JAMA Study Finds No Link Between Prenatal Acetaminophen and Neurodevelopmental Risks

On June 29, 2026, a large-scale sibling-matched cohort study published in JAMA Internal Medicine reported no association between prenatal acetaminophen exposure and the risk of autism spectrum disorder or attention-deficit/hyperactivity disorder in children. By comparing siblings with discordant exposure, the researchers controlled for confounding genetic and environmental factors that had skewed previous observational research. The study reported that the lack of association persisted regardless of the trimester of exposure, the dosage, or the frequency of use, providing critical data to the medical community. This peer-reviewed study provides significant defense arguments for manufacturers in the ongoing Acetaminophen Products Liability Litigation, where plaintiffs have long claimed the common pain reliever caused childhood neurodevelopmental disorders. While federal multidistrict claims under MDL 3043 were previously dismissed, state-court actions continue to hinge on general causation disputes that this new data will directly influence.